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SUMMARY
The collision of the tuberculosis (TB) and human immunodeficiency virus (HIV) epidemics has 
been described as a ‘syndemic’ due to the synergistic impact on the burden of both diseases. This 
paper explains the urgent need for practitioners and policy makers to address a third epidemic that 
exacerbates TB, HIV and TB-HIV. Tobacco use is the leading cause of preventable death 
worldwide. Smoking is more prevalent among persons diagnosed with TB or HIV. Smoking is 
associated with tuberculous infection, TB disease and poorer anti-tuberculosis treatment 
outcomes. It is also associated with an increased risk of smoking-related diseases among people 
living with HIV, and smoking may also inhibit the effectiveness of life-saving ART. In this paper, 
we propose integrating into TB and HIV programmes evidence-based strategies from the ‘MPO-
WER’ package recommended by the World Health Organization’s Framework Convention on 
Tobacco Control. Specific actions that can be readily incorporated into current practice are 
recommended to improve TB and HIV outcomes and care, and reduce the unnecessary burden of 
death and disease due to smoking.
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The collision of the human immunodeficiency virus (HIV) and tuberculosis (TB) epidemics 
has been described as a syndemic due to the synergistic impact on the burden of disease.1 
People living with HIV (PLHIV) are more likely to progress from tuberculous infection to 
TB disease,2 and TB remains the leading cause of death among PLHIV.3 The global scale-
up of both antiretroviral therapy (ART) for PLHIV and the collaborative TB-HIV activities 
recommended by the World Health Organization (WHO) have contributed to a 36% decline 
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in TB deaths among PLHIV between 2004 and 2012.4 Although TB and HIV are leading 
causes of death due to infection, tobacco use remains the overall leading cause of death 
worldwide. Separate guidelines on how to address smoking among TB or HIV patients by 
the WHO and other organisations exist; however, these do not highlight the critical linkages 
between TB, HIV and smoking. This Perspective underlines the urgent need to adopt a 
synergistic approach and identifies how recommended measures of tobacco control can also 
be applied effectively in TB and HIV practice.
IMPACT OF TOBACCO USE ON PERSONS WITH TB, HIV AND TB-HIV
Taking lessons learned from the TB-HIV collaboration, there is growing recognition of the 
need to address other health conditions and risk factors that exacerbate the global burden of 
TB5,6 or HIV.7 Tobacco use is the leading preventable cause of death globally,8 and 
smoking negatively affects efforts to prevent and treat TB and HIV infection. Smoking is 
associated with tuberculous infection, TB disease and poor anti-tuberculosis treatment 
outcomes (i.e., recurrent disease and mortality).9,10 An estimated 16% of all TB cases could 
be prevented if smoking and exposure to secondhand smoke (SHS) were eliminated.5
Based on limited available data, the observed prevalence of smoking among TB patients has 
been reported to be double or only slightly greater than the prevalence in the general 
population, depending on the setting.11–14 Of note, both reported cases of TB15 and the 
prevalence of smoking16 are higher among men than women in most countries.
PLHIV who smoke suffer disproportionally from non-communicable diseases (NCDs) 
compared to non-smoking PLHIV. Compared to PLHIV who do not, PLHIV who smoke 
have an increased risk of developing lung and other forms of cancer, are more likely to 
develop bacterial pneumonia, Pneumocystis jiroveci pneumonia (PJP), chronic obstructive 
pulmonary disease (COPD), heart disease, thrush or oral hairy leukoplakia,17,18 have a 
greater rate of progression from HIV infection to AIDS and have a poorer response to life-
saving ART.19,20 Based on available data, smoking prevalence among PLHIV exceeds that 
in the general population.11,18,21–23
TB and HIV treatment requires multiple interactions with the health system. The repeated 
visits provide health care workers with ample opportunity for the screening, diagnosis and 
management of NCDs and behavioural risk factors, such as tobacco use. In the present 
paper, we propose expanding the scope of TB-HIV collaborative activities to include the 
assessment, followed by the implementation, of evidence-based strategies to prevent or 
promote cessation of tobacco use among TB, HIV and TB-HIV patients (hereafter, TB-HIV 
refers to patients with TB, HIV or TB and HIV).
APPLYING ‘MPOWER’ EVIDENCE-BASED INTERVENTIONS TO TB AND HIV 
PRACTICE
The evidence-based ‘MPOWER’ package was developed by the WHO to catalyse global 
efforts to address the tobacco epidemic. ‘MPOWER’ includes the following six key 
recommendations: ‘Monitor’, ‘Protect’, ‘Offer’, ‘Warn’, ‘Enforce’ and ‘Raise’.24 Between 
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2007 and 2010, the implementation of ‘MPOWER’ resulted in an estimated 14.8 million 
fewer smokers, averting a total of 7.4 million deaths attributable to smoking.25 By 
encouraging TB and HIV practitioners and programmes to address tobacco use, we can 
extend the implementation of ‘MPOWER’ measures and thereby reduce tobacco-related 
morbidity and mortality among TB-HIV patients and potentially improve anti-tuberculosis 
treatment and HIV therapeutic outcomes.
Practical ways in which TB and HIV practitioners can engage in interventions that are 
feasible and relevant to routine care are discussed, focusing on ‘MPOW’ for individual 
practitioners and ‘E’ for programme and institution managers. ‘R’—Raise tobacco taxes—is 
a high-impact strategy that requires actions beyond the direct control of individual 
practitioners.
Monitor
Data on tobacco use, cessation and exposure to SHS are needed to guide the development of 
interventions for TB-HIV patients at individual, community and population levels. ‘Tobacco 
Questions for Surveys’ (TQS) are rigorously pre-tested questions that can be inserted into 
existing TB and HIV recording and reporting forms, prevalence and drug resistance surveys, 
and other routine data collection systems.26 The assessment and recording of individual 
patient smoking status as part of standard care is also essential for effective counselling and 
support. Accurate assessment is important and may require revised questions or cotinine 
testing to address under-reporting due to recent or ‘temporary’ quitters as a result of TB-
induced coughing.
Protect
There is no safe level of exposure to SHS, which contributes to a range of serious diseases, 
including cardiovascular disease and lung cancer.27–29 Smokefree health care environments 
have been identified as a key strategy for institutions and practitioners to protect patients, 
staff and visitors.30,31 Implementing smokefree environments should be part of routine 
infection control duties of TB-HIV staff. Staff can post ‘no smoking’ signs, and all staff 
should be responsible for providing information to patients and families and enforcing 
policy. To assist implementation, trained staff can provide brief support to patients and 
families to help them quit smoking, as described below.
Staff from TB and HIV programmes can advise patients and their families on how to make 
their homes smoke free and eliminate SHS exposure. This protects against the general 
adverse impacts of SHS on health,32,33 and especially protects TB-HIV patients who have 
heightened vulnerability. Smokefree homes can also support cessation by reducing smoking 
cues,34 and this may assist TB-HIV patients to quit. Brief counselling and provision of 
information, education and communication (IEC) materials can also be effective,35 and can 
be successfully incorporated into clinical encounters36,14,37 and practitioner home visits.35
Offer
Quitting produces immediate and long-term health benefits.38 The most effective 
interventions developed and tested for the general population include brief advice to quit and 
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guidance about available support, one-to-one or group counselling, and provision of 
pharmacotherapy.39 In countries where pharmacotherapy is not included on the essential 
drug formularies, brief advice and counselling alone can be effective.40,41 Behavioural 
support has been shown to be generally effective in low- and middle-income countries;42 the 
‘ASSIST’ trial found that behavioural support, with or without buproprion, is effective in 
promoting cessation among smokers with suspected TB.36 Dogar and Siddiqi provide an 
overview of evidence-based models of behavioural support that may be adapted for local 
use.43 Data on cessation of tobacco use among TB-HIV patients are limited; however, 
available trial evidence indicates that the standard recommended interventions are 
feasible,44 and can be effective.45 Advice and counselling should be tailored to the needs of 
TB-HIV patients, while pharmacotherapy options should be evaluated by clinicians to 
ensure compatibility with anti-tuberculosis and/or ART treatment regimens.
Warn
Specific information for people with tuberculous infection, TB disease and/or HIV and their 
families about the link between tobacco use and TB and the potential for reducing the 
effectiveness of ART is crucial and may have the greatest resonance. Practitioners are 
advised to use all available channels to educate and inform people about tobacco risks.24
Enforce
Institution and programme managers can help protect TB-HIV patients by enacting their 
own regulations to ban the institution and staff from undertaking or accepting tobacco 
promotions or sponsorship.8
A SIGNIFICANT PUBLIC HEALTH OPPORTUNITY
Failure to address smoking among men, women and children with these conditions may 
otherwise undermine efforts to improve TB-HIV treatment outcomes. Moreover, the harm 
caused by tobacco and smoking is preventable.8 Tobacco control measures should be 
implemented for TB-HIV patients, their families and communities to tackle a modifiable 
risk factor that will potentially enhance and extend the quality of people’s lives. Integrating 
evidence-based ‘M’, ‘P’, ‘O’, ‘W’ and ‘E’ measures into TB and HIV practice requires 
minimal resource demands. The recommended measures are low cost and can be readily 
incorporated into day-to-day patient practice; also, they do not require new equipment, 
complex training or structural changes to health facilities.
For tobacco control practitioners, organisations and governments, the patient encounters 
inherent in TB-HIV care offer a valuable gateway to address tobacco use. The sheer number 
of patients constitutes a major public health opportunity. In 2012, an estimated 8.6 million 
people developed TB, 1.3 million died from the disease (including 320 000 deaths among 
PLHIV) and there were 35.3 million adults and children living with HIV. The sex and socio-
economic profile of TB patients—often affecting more men and the poorer segments of the 
community—also coincides with groups that generally have a higher prevalence of 
smoking.15,16 The successful integration of tobacco control measures into TB-HIV care 
could provide a model platform from where other risk factors (e.g., substance abuse) and 
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conditions (e.g., diabetes, COPD, hypertension) might be addressed to improve the overall 
health of patients.
Collaboration between TB, HIV and tobacco control programmes would afford benefits 
such as resource sharing, enhanced reach to vulnerable populations and the potential to 
make logical connections within health systems that will enable more comprehensive 
patient-centred prevention and care. Guidelines for the treatment of TB and HIV should 
include recommendations on addressing smoking and other forms of tobacco use. These 
must go beyond the traditional territory of encouraging cessation and encompass the wider, 
critically relevant underpinning areas of ‘MPOWER’. Screening for tobacco use among 
people with suspected or diagnosed TB-HIV should be viewed as essential: first, to address 
the world’s leading cause of death, and second, as a component of TB-HIV care to maximise 
the efficacy of TB-HIV prevention and treatment services.
The colliding epidemiology of TB, HIV and tobacco use provides not only a compelling 
case for action, but also an important opportunity to address the leading preventable cause of 
death and to ensure that TB-HIV patients can realise the benefits of anti-tuberculosis 
treatment, TB preventive therapy and lifesaving ART.
Acknowledgments
The global tobacco control grants programme, managed jointly by the International Union Against Tuberculosis 
and Lung Disease (Edinburgh, Scotland, UK) and the Campaign for Tobacco Free Kids (Washington, DC, USA), is 
funded by the Bloomberg Initiative to Reduce Tobacco Use.
References
1. Kwan CK, Ernst JD. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev. 2011; 
24:351–376. [PubMed: 21482729] 
2. Martinson, N.; Omar, T.; Rakgokong, M.; Moroe, E.; Lebina, L.; Variava, E. Undiagnosed 
infectious TB in adult home deaths: South Africa. 20th Conference on Retroviruses and 
Opportunistic Infections; 3–6 March 2013; Atlanta, GA, USA. Abstract 837
3. Siika AM, Yiannoutsos CT, Wools-Kaloustian KK, et al. Active tuberculosis is associated with 
worse clinical outcomes in HIV-infected African patients on antiretroviral therapy. PLOS ONE. 
2013; 8:e53022. [PubMed: 23301015] 
4. UNAIDS. AIDS by the numbers. Geneva, Switzerland: UNAIDS; 2013. http://www.unaids.org/
sites/default/files/media_asset/JC2571_AIDS_by_the_numbers_en_1.pdf [Accessed April 2015]
5. Lönnroth K, Castro KG, Chakaya JM, et al. Tuberculosis control and elimination 2010–50: cure, 
care and social development. Lancet. 2010; 375:1814–1829. [PubMed: 20488524] 
6. Creswell J, Raviglione M, Ottmani S, et al. Tuberculosis and non-communicable diseases: neglected 
links and missed opportunities. Eur Respir J. 2011; 37:1269–1282. [PubMed: 20947679] 
7. Nigatu T. Integration of HIVand non-communicable diseases in health care delivery in low- and 
middle-income countries. Prev Chronic Dis. 2012; 9:110–331.
8. World Health Organization. WHO report on the global tobacco epidemic, 2013: enforcing bans on 
tobacco advertising, promotion and sponsorship. Geneva, Switzerland: WHO; 2013. 
9. World Health Organization. AWHO/The Union monograph on TB and tobacco control: joining 
efforts to control two related global epidemics. Geneva, Switzerland: WHO; 2007. 
10. Yen YF, Yen MY, Lin YS, et al. Smoking increases risk of recurrence after successful anti-
tuberculosis treatment: a population-based study. Int J Tuberc Lung Dis. 2014; 18:492–498. 
[PubMed: 24670708] 
Jackson-Morris et al. Page 5













11. Ramin B, Kam D, Feleke B, Jacob B, Jha P. Smoking, HIV and non-fatal tuberculosis in an urban 
African population. Int J Tuberc Lung Dis. 2008; 12:695–697. [PubMed: 18492341] 
12. Brunet L, Pai M, Davids V, Ling D, Paradis G, Lenders L. High prevalence of smoking among 
patients with suspected tuberculosis in South Africa. Eur Respir J. 2011; 38:139–146. [PubMed: 
21148230] 
13. Wang J, Shen H. Review of cigarette smoking and tuberculosis in China: intervention is needed for 
smoking cessation among tuberculosis patients. BMC Public Health. 2009; 9:292. [PubMed: 
19674472] 
14. Louwagie GMC, Okuyemi KS, Ayo-Yusuf OA. Efficacy of brief motivational interviewing on 
smoking cessation at tuberculosis clinics in Tshwane, South Africa: a randomised controlled trial. 
Addiction. 2014; 109:1942–1952. [PubMed: 24962451] 
15. Neyrolles O, Quintana-Murci L. Sexual inequality in tuberculosis. PLOS MED. 2009; 6:e1000199. 
[PubMed: 20027210] 
16. Hitchman SC, Fong GT. Gender empowerment and female-to-male smoking prevalence ratios. 
Bull World Health Organ. 2011; 89:195–202. [PubMed: 21379415] 
17. US Department of Health and Human Services, AIDS.gov. Smoking and tobacco use [Internet]. 
Washington, DC, USA: US Department of Health and Human Services; 2013. http://
www.aids.gov/hiv-aids-basics/staying-healthy-with-hiv-aids/taking-care-of-yourself/smoking-
tobacco-use/ [Accessed April 2015]
18. Petrosillo N, Cicalini S. Smoking and HIV: time for change? BMC Med. 2013; 11:16. [PubMed: 
23339539] 
19. Feldman JG, Minkoff H, Schneider MF, et al. Association of cigarette smoking with HIV 
prognosis among women in the HAART era: a report from the women’s interagency HIV study. 
Am J Public Health. 2006; 96:1060–1065. [PubMed: 16670229] 
20. Mdodo, R.; Frazier, E.; Mattson, C.; Sutton, M.; Brooks, J.; Skarbinski, J. Cigarette smoking 
among HIV+ adults in care: Medical Monitoring Project, US, 2009. 20th Conference on 
Retroviruses and Opportunistic Infections; 3–6 March 2013; Atlanta, GA, USA. Abstract 775
21. Lifson AR, Neuhaus J, Arribas JR, et al. Smoking-related health risks among persons with HIV in 
the strategies for management of antiretroviral therapy clinical trial. Am J Public Health. 2010; 
100:1896–1903. [PubMed: 20724677] 
22. Mondy KE, Gottdiener J, Turner Overton E, et al. High prevalence of echocardiographic 
abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy. Clin 
Infect Dis. 2011; 52:378–386. [PubMed: 21217185] 
23. Waweru P, Anderson R, Steel H, Venter W, Murdoch D, Feldman C. The prevalence of smoking 
and the knowledge of smoking hazards and smoking cessation strategies among HIV-positive 
patients in Johannesburg, South Africa. S Afr Med J. 2013; 103:858–860. [PubMed: 24148173] 
24. World Health Organisation. WHO report on the global tobacco epidemic, 2008: the MPOWER 
package. Geneva, Switzerland: WHO; 2008. 
25. Levy DT, Ellis JA, Mays D, Huang AT. Smoking-related deaths averted due to three years of 
policy progress. Bull World Health Organ. 2013; 91:501–518. [PubMed: 23825877] 
26. Global Adult Tobacco Survey Collaborative Group. Tobacco questions for surveys: a subset of key 
questions from the Global Adult Tobacco Survey (GATS). 2. Atlanta, GA, USA: US Centers for 
Disease Control and Prevention; 2011. 
27. Olasky SJ, Levy D, Moran A. Secondhand smoke and cardiovascular disease in low and middle 
income countries: a case for action. Glob Heart. 2012; 7:151–160. [PubMed: 23139915] 
28. Wilhelm-Benartzi CS, Christensen BC, Koestler DC, et al. Association of secondhand smoke 
exposures with DNA methylation in bladder carcinomas. Cancer Causes Control. 2011; 22:1205–
1213. [PubMed: 21660454] 
29. Vardavas CI, Mpouloukaki I, Linardakis M, Ntzilepi P, Tzanakis N, Kafatos A. Secondhand 
smoke exposure and excess heart disease and lung cancer mortality among hospital staff in Crete, 
Greece: a case study. Int J Environ Res Public Health. 2008; 5:125–129. [PubMed: 19139529] 
30. International Union Against Tuberculosis and Lung Disease. Tobacco-free healthcare: a tobacco-
free futures action guide. Paris, France: The Union; 2009. http://www.theunion.org/what-we-do/
publications/english/pubtc_tobaccofreehealthcare-en.pdf [Accessed April 2015]
Jackson-Morris et al. Page 6













31. Lin Y, Fraser T. A review of smoke-free health care in mainland China. Int J Tuberc Lung Dis. 
2011; 15:453–458. [PubMed: 21396202] 
32. Semple S, Garden C, Coggins M, Whelan P, Cowie H, Sanchez-Jiminez A. Contribution of solid 
fuel, gas combustion or tobacco smoke to indoor air pollutant concentrations in Irish and Scottish 
homes. Indoor Air. 2012; 22:212–223. [PubMed: 22007695] 
33. Prokhorov AV, Hudmon KS, Marani SK, et al. Eliminating second-hand smoke from Mexican-
American households: outcomes from project Clean Air-Safe Air (CASA). Addict Behav. 2013; 
38:1485–1492. [PubMed: 23085392] 
34. Wilson I, Semple S, Mills LM, et al. REFRESH – reducing families’ exposure to secondhand 
smoke in the home: a feasibility study. Tob Control. 2013; 22:e8. [PubMed: 22615325] 
35. Kegler MC, Escoffey C, Bundy L, et al. Pilot study results from a Brief Intervention to Create 
Smoke-Free Homes. J Environ Public Health. 2012; 2012:951–426.
36. Siddiqi K, Khan A, Ahmad M, et al. Action to Stop Smoking in Suspected Tuberculosis (ASSIST) 
in Pakistan: a cluster randomized, controlled trial. Ann Intern Med. 2013; 158:667–675. [PubMed: 
23648948] 
37. Sereno AB, Soares EC, Lapa E, Silva JR, et al. Feasibility study of a smoking cessation 
intervention in directly observed therapy short-course tuberculosis treatment clinics in Rio de 
Janeiro, Brazil. Rev Panam Salud Publica. 2012; 32:451–456. [PubMed: 23370189] 
38. Jha P, Ramasundarahettige C, Landsman V, et al. 21st century hazards of smoking and benefits of 
cessation in the United States. N Engl J Med. 2013; 368:341–350. [PubMed: 23343063] 
39. Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking 
cessation. Cochrane Database Syst Rev. 2012; 10:CD008286. [PubMed: 23076944] 
40. Varghese C, Kaur J, Desai NG, et al. Initiating tobacco cessation services in India: challenges and 
opportunities. WHO South-East Asia J Public Health. 2012; 1:159–168.
41. International Union Against Tuberculosis and Lung Disease. Tobacco cessation interventions for 
tuberculosis patients: a guide for low-income countries. Paris, France: The Union; 2008. 
42. Dogar O, Bullen C, Novotny TE, Siddiqi K. Smoking cessation and respiratory disease in low-
income and middle-income countries. Lancet Respir Med. 2013; 1:e23–e24. [PubMed: 24429210] 
43. Dogar O, Siddiqi K. An evidence-based guide to smoking cessation therapies. Nurse Prescribing. 
2013; 11:543–548.
44. Humfleet GL, Hall SM, Delucchi KL, Dilley JW. A randomized clinical trial of smoking cessation 
treatments provided in HIV clinical care settings. Nicotine Tob Res. 2013; 15:1436–1445. 
[PubMed: 23430708] 
45. Elzi L, Spoerl D, Voggensperger J, et al. A smoking cessation programme in HIV-infected 
individuals: a pilot study. Antiviral Therapy. 2006; 11:787–795. [PubMed: 17310823] 
Jackson-Morris et al. Page 7
Int J Tuberc Lung Dis. Author manuscript; available in PMC 2016 February 12.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
